Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | MARK3 | P27448 | 2/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.47 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.47 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.47 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.47 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.47 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL28657307 | 0.86 | ROCK2 (0.45) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| SCHEMBL14990455 | 0.85 | ROCK2 (0.48) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| SCHEMBL12925684 | 0.83 | ROCK2 (0.50) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| SCHEMBL28657311 | 0.83 | ROCK2 (0.47) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| SCHEMBL28644536 | 0.83 | ROCK2 (0.47) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| SCHEMBL31537 | 0.83 | ROCK2 (0.47) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Bromide SCHEMBL28709695 | 0.82 | ROCK2 (0.46) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Hydrochloric Acid SCHEMBL999448 | 0.82 | ROCK2 (0.47) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Iodide SCHEMBL28700199 | 0.82 | ROCK2 (0.46) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Formic Acid SCHEMBL28686548 | 0.80 | ROCK2 (0.43) | ROCK2ROCK1PRKCDPLK4MARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111909088-B | Method for preparing isoquinoline hydrochloride intermediate and Rho kinase inhibitor by using BTC/Ph3PO chloro-system | 浙江工业大学 | 2022-03-01 | — | — | CN | claimed |
| CN-111909088-A | Utilizing BTC/Ph3Method for preparing isoquinoline hydrochloride intermediate and Rho kinase inhibitor by PO chloro system | 浙江工业大学 | 2020-11-10 | — | — | CN | claimed |
| EP-1852421-B1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO (JP) | 2011-05-04 | — | — | EP | claimed |
| US-7872136-B2 | Process for production of 4-fluoroisoquinoline-5-sulfonyl halide or salt thereof | KOWA CO., LTD. (JP) | 2011-01-18 | — | — | US | claimed |
| US-20090209765-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO., LTD. (JP) | 2009-08-20 | — | — | US | claimed |
| EP-1852421-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | Kowa Company, Ltd. (JP) | 2007-11-07 | — | — | EP | claimed |
| CN-113582926-B | Synthesis method of 4-fluoroisoquinoline-5-sulfonyl chloride or pharmaceutically acceptable salt thereof | 安徽有吉医药科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-111909088-B | Method for preparing isoquinoline hydrochloride intermediate and Rho kinase inhibitor by using BTC/Ph3PO chloro-system | 浙江工业大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-113582926-A | Synthesis method of 4-fluoroisoquinoline-5-sulfonyl chloride or pharmaceutically acceptable salt thereof | 安徽有吉医药科技有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-111909088-A | Utilizing BTC/Ph3Method for preparing isoquinoline hydrochloride intermediate and Rho kinase inhibitor by PO chloro system | 浙江工业大学 | 2020-11-10 | — | — | CN | disclosed |
| EP-1852421-B1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO (JP) | 2011-05-04 | — | — | EP | disclosed |
| EP-1852421-B1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-7872136-B2 | Process for production of 4-fluoroisoquinoline-5-sulfonyl halide or salt thereof | KOWA CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7872136-B2 | Process for production of 4-fluoroisoquinoline-5-sulfonyl halide or salt thereof | KOWA CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090209765-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209765-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-1852421-A4 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO (JP) | 2009-07-08 | — | — | EP | disclosed |
| EP-1852421-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | Kowa Company, Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1852421-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | Kowa Company, Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006090783-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO., LTD. (JP) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209765-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | SALL4, STS, SFPQ | ROCK2 3563/4885ROCK1 4159/4885PRKCD 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.